Hi AR, thanks for post re: Celebrex. I guess you posted to me because I keep bitching about pain from RA.<g> But maybe it was due to curiosity about investing in this stuff. I note with some interest that biotechs and drugs are arousing more interest these past few weeks, maybe because the sector is just due for a rotation after Happy Girl bought up all the YHOO?<g>
The major competitor to Celebrex is Vioxx, also a Cox-2 inhibitor, by Merck, also expected to be approved this year. Hey, you know what, I actually understand this stuff scientifically, not like telecoms and such. So, if the article says that Enbrel or Arava are competitors, wrong, they work in a completely different way, although they are going to be big sellers, too.
You may not realize that the projected profits from these (Cox-2 inhibitors) drugs are already built into analyst projections for Monsanto, Pfizer and Merck.
The best web site I have found for investors interested in new drugs is:
biocognizance.com
Click on the "new therapeutics" part. |
